Results 21 to 30 of about 530,239 (305)

Melanoma

Clinical Radiology, 2004
The incidence of malignant melanoma in the UK is still rising despite public health warnings about the risks of excessive sun exposure. This aggressive tumour can metastasize to virtually any organ, even years after resection of the primary lesion and cause a variety of radiological appearances.
E, Kalkman, G, Baxter
openaire   +4 more sources

Measles virus causes immunogenic cell death in human melanoma [PDF]

, 2011
NoOncolytic viruses (OV) are promising treatments for cancer, with several currently undergoing testing in randomised clinical trials. Measles virus (MV) has not yet been tested in models of human melanoma.
Russell, S, Selby, P., Hadac, E., Donnelly, Oliver G, Jennings, V., Errington-Mais, F., Melcher, Alan A, Hadac, Elizabeth, Bond, J, Melcher, A.A., Bond, Jacquelyn, Selby, P, Bond, J., Peach, H., Vile, Richard, Steele, L., Vile, R., Hadac, E, Donnelly, O.G., Russell, Stephen, Harrington, K.J., Harrington, K, Peach, Howard, Steele, Lynette, Melcher, AA, Errington-Mais, Fiona, Harrington, Kevin, Russell, S., Phillips, Roger M., Pandha, H.S., Selby, Peter, Errington-Mais, F, Jennings, V, Scott, K, Phillips, RM, Phillips, Roger M, Scott, K., Pandha, Hardev, Vile, R, Jennings, Victoria, Steele, L, Pandha, H, Scott, Karen, Donnelly, OG, Peach, H   +44 more
core   +1 more source

The State of Melanoma: Emergent Challenges and Opportunities [PDF]

, 2021
Five years ago, the Melanoma Research Foundation (MRF) conducted an assessment of the challenges and opportunities facing the melanoma research community and patients with melanoma.
Soengas, Maria S, Johnson, Douglas B, Swetter, Susan M, Fox, Bernard A, Atkins, Michael B, Jeter, Joanne M, Ferris, Laura K, Nelson, Kelly C, Hernando, Eva, Kirkwood, John M, Leachman, Sancy A, Aguirre-Ghiso, Julio A, Mays, Darren, Hanks, Brent A, Flaherty, Keith T, Chandra, Sunandana, Foundation, on behalf of the Melanoma Research, Sosman, Jeffrey A, Herlyn, Meenhard, Sullivan, Ryan J, Sondak, Vernon K, Merlino, Glenn, Cassidy, Pamela B, Pavlick, Anna C, Gershenwald, Jeffrey E, Chapman, Paul B, Tsao, Hensin, Eroglu, Zeynep, Grossman, Douglas, Gerhsenwald, Jeffrey E, Gibney, Geoffrey T, Hanniford, Douglas, Curiel-Lewandrowski, Clara, Fisher, David E, Weeraratna, Ashani T, Tawbi, Hussein A, Daud, Adil, Khleif, Samir N, Soengas, MS   +38 more
core   +1 more source

Heterogeneity in Melanoma

Cancers, 2022
There is growing evidence that tumour heterogeneity has an imperative role in cancer development, evolution and resistance to therapy. Continuing advancements in biomedical research enable tumour heterogeneity to be observed and studied more critically.
Mei Fong Ng, Jacinta L. Simmons, Glen M. Boyle   +2 more
openaire   +5 more sources

Differential chemosensitivity to antifolate drugs between RAS and BRAF melanoma cells. [PDF]

, 2014
BACKGROUND: The importance of the genetic background of cancer cells for the individual susceptibility to cancer treatments is increasingly apparent.
Ferguson, J., Claudia Wellbrock, Erice, O., Margison, G.P., Goicoechea, I., Geoffrey P Margison, Margison, Geoffrey P, Wellbrock, C., Wellbrock, Claudia, Jennnifer Ferguson, Arozarena, Imanol, Goicoechea, Ibai, Imanol Arozarena, Ferguson, Jennnifer, Erice, Oihane, Oihane Erice, Ibai Goicoechea   +16 more
core   +1 more source

Dimethyl fumarate combined with cisplatin at subcytotoxic doses sensitizes cervical cancer toward ferroptosis and apoptosis through GSH restriction and p53 (re)activation

Molecular Oncology, EarlyView.
Dimethyl fumarate (DMF) reduces growth of HPV‐positive cervical cancer spheroids and induces ferroptosis in cervical cancer cells via blocking SLC7A11/Glutathione (GSH) axis. Combination of subcytotoxic doses of DMF and cisplatin (CDDP) further suppresses spheroid growth and drives cell death in 2D culture models.
Carolina Punziano, Giuseppina Minopoli, Simona Romano, Laura Marrone, Katia Aquilano, Maria Lina Tornesello, Raffaella Faraonio   +6 more
wiley   +1 more source

A randomised trial evaluating Bevacizumab as adjuvant therapy following resection of AJCC stage IIB, IIC and III cutaneous melanoma : an update [PDF]

, 2008
At present, there are no standard therapies for the adjuvant treatment of malignant melanoma. Patients with primary tumours with a high-Breslow thickness (stages IIB and IIC) or with resected loco-regional nodal disease (stage III) are at high risk of ...
Middleton, M. (Mark), Corrie, P, Middleton, M, Dunn, J., East, C, Lorigan, P; id_orcid, Hern, A., Biswas, S., Wrigley, J., Lorigan, P., Wrigley, J, Dunn, Janet A., Marshall, A. (Andrea), Corrie, P., East, C., Marshall, A.   +15 more
core   +1 more source

33 | A single center, real world experience with hedgehog pathway inhibitors in advanced basal cell carcinoma

Dermatology Reports
Background: Cutaneous basal cell carcinoma (cBCC) is the most common non melanocytic skin cancer, with a worldwide increased incidence. Basal cell carcinomas are heterogeneous, ranging from superficial or nodular lesions with a good prognosis to ...
Italian Melanoma Intergroup
doaj   +1 more source

Establishment of a humanized patient‐derived xenograft mouse model of high‐grade serous ovarian cancer for preclinical evaluation of combination immunotherapy

Molecular Oncology, EarlyView.
We have established a humanized orthotopic patient‐derived xenograft (Hu‐oPDX) mouse model of high‐grade serous ovarian cancer (HGSOC) that recapitulates human tumor–immune interactions. Using combined anti‐PD‐L1/anti‐CD73 immunotherapy, we demonstrate the model's improved biological relevance and enhanced translational value for preclinical ...
Luka Tandaric, Line Bjørge, Martine Rott Lode, Cecilie Fredvik Torkildsen, Pia Aehnlich, Rammah Elnour, Daniela Elena Costea, Lars Andreas Akslen, Liv Cecilie Vestrheim Thomsen, Emmet McCormack, Katrin Kleinmanns   +10 more
wiley   +1 more source

p63 is an alternative p53 repressor in melanoma that confers chemoresistance and a poor prognosis [PDF]

, 2013
The role of apoptosis in melanoma pathogenesis and chemoresistance is poorly characterized. Mutations in TP53 occur infrequently, yet the TP53 apoptotic pathway is often abrogated.
Graf, M, Mesher, D, Francesca Moretti, Chiorino, G, A. Chikh, Costanzo, A, M. Graf, D. Bergamaschi, Leigh, IM, Cerio, R, Maria Scatolini, Chong, SLP, C. M. Proby, Anissa Chikh, Antonio Costanzo, Matin, RN, Moretti, F, COSTANZO, ANTONIO, Charlotte M. Proby, Valentina Senatore, C. A. Harwood, Senatore, V, I. M. Leigh, D. Mesher, Harwood, CA, Catherine A. Harwood, R. N. Matin, Stephanie Law Pak Chong, Paolo Sanza’, Rino Cerio, R. Cerio, Bergamaschi, D, David Mesher, P. Sanza', M. Scatolini, Irene M. Leigh, S. L. Pak, Rubeta N. Matin, Proby, CM, V. Senatore, Daniele Bergamaschi, F. Moretti, Chikh, A, Sanza', P, Scatolini, M, Giovanna Chiorino, G. Chiorino, Manuela Graf   +47 more
core   +1 more source